| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maryam Tariq, Muhammad Iqbal Afridi, Dua Saleem, Sarmad Pirzad. Catatonic Schizophrenia: Cases with Possible Genetic Predisposition. Cureus. vol 11. issue 4. 2020-09-30. PMID:31263634. |
the diagnosis of catatonic schizophrenia was made, and the patient was started orally on aripiprazole and lorazepam. |
2020-09-30 |
2023-08-13 |
Not clear |
| Maryam Tariq, Muhammad Iqbal Afridi, Dua Saleem, Sarmad Pirzad. Catatonic Schizophrenia: Cases with Possible Genetic Predisposition. Cureus. vol 11. issue 4. 2020-09-30. PMID:31263634. |
we here discuss a possible genetic predisposition to catatonic schizophrenia and its initial improvement with lorazepam and subsequent treatment with olanzapine proving to be more efficacious than aripiprazole. |
2020-09-30 |
2023-08-13 |
Not clear |
| Richard E Hodgso. Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting. ClinicoEconomics and outcomes research : CEOR. vol 11. 2020-09-30. PMID:31616168. |
antipsychotics are an effective treatment option for patients with schizophrenia and several long-acting injectables (lais), including risperidone, olanzapine, paliperidone, and aripiprazole are available in the uk. |
2020-09-30 |
2023-08-13 |
Not clear |
| Suneeta James, Chaya Kapugama, Mohammed Al-Uzr. Corrigendum to "Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia". Case reports in psychiatry. vol 2019. 2020-09-30. PMID:31637079. |
corrigendum to "use of aripiprazole long acting injection in negative symptoms of schizophrenia". |
2020-09-30 |
2023-08-13 |
Not clear |
| Hiroyuki Kamei, Yuki Homma, Ippei Takeuchi, Genta Hajitsu, Kaori Tozawa, Masakazu Hatano, Aiko Fukui, Manako Hanya, Shigeki Yamada, Nakao Iwat. Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 18. issue 1. 2020-09-30. PMID:31958905. |
acceptance of the deltoid muscle injection of aripiprazole long-acting injectable in the patients with schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masan. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 18. issue 1. 2020-09-30. PMID:31958916. |
effectiveness and tolerability of switching to aripiprazole once monthly from antipsychotic polypharmacy and/or other long acting injectable antipsychotics for patients with schizophrenia in routine practice: a retrospective, observation study. |
2020-09-30 |
2023-08-13 |
Not clear |
| Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masan. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 18. issue 1. 2020-09-30. PMID:31958916. |
this study was done for collection of real world data of aripiprazole once monthly (aom) in patients with schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwat. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatric disease and treatment. vol 12. 2020-09-29. PMID:27932884. |
a randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. |
2020-09-29 |
2023-08-13 |
Not clear |
| Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwat. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatric disease and treatment. vol 12. 2020-09-29. PMID:27932884. |
there has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. |
2020-09-29 |
2023-08-13 |
Not clear |
| Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwat. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatric disease and treatment. vol 12. 2020-09-29. PMID:27932884. |
we conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (umin000011194). |
2020-09-29 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Peter J Weide. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatric disease and treatment. vol 15. 2020-09-29. PMID:31686823. |
assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. |
2020-09-29 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Peter J Weide. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatric disease and treatment. vol 15. 2020-09-29. PMID:31686823. |
here, nnt, nnh, and lhh were used to evaluate the clinical usefulness of aripiprazole lauroxil in patients with an acute schizophrenia exacerbation. |
2020-09-29 |
2023-08-13 |
Not clear |
| Masaru Nakamura, Takahiko Nagamin. PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT. Innovations in clinical neuroscience. vol 15. issue 3-4. 2020-09-28. PMID:29707420. |
prolactin levels in patients with schizophrenia who were switched from daily to once-monthly aripiprazole treatment. |
2020-09-28 |
2023-08-13 |
Not clear |
| Trisna Marni, Bahagia Loebis, Vita Camellia, Elmeida Effendy, Nazli Mahdinasari Nasutio. The Difference of Fasting Blood Sugar of Male Patients with Schizophrenia Treated with Flexible Dose between Aripiprazole and Risperidone in Medan, Indonesia. Open access Macedonian journal of medical sciences. vol 7. issue 9. 2020-09-28. PMID:31198452. |
the difference of fasting blood sugar of male patients with schizophrenia treated with flexible dose between aripiprazole and risperidone in medan, indonesia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32026379. |
once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: a multicentre, observational study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32026379. |
to evaluate the efficacy and impact of long-acting injectable (lai) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (sud). |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32112360. |
correction to: once‑monthly long‑acting injectable aripiprazole for the treatment of patients with schizophrenia and co‑occurring substance use disorders: a multicentre, observational study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Joseph Kuo, Shih-Ku Li. Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder. Case reports in psychiatry. vol 2020. 2020-09-28. PMID:32148990. |
extended-release injectable (eri) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar i disorder. |
2020-09-28 |
2023-08-13 |
Not clear |
| Maria-Ioanna Stefanou, Debora Vittore, Ines Wolz, Stefan Klingberg, Dirk Wildgrube. Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32425825. |
recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Daisy Ng-Mak, Andrew Messali, Ahong Huang, Li Wang, Antony Loebe. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. The American journal of managed care. vol 25. issue 14 Suppl. 2020-09-23. PMID:31365818. |
this study compared the risk of hospitalization among adults with schizophrenia being treated with equivalent dose ranges of lurasidone versus aripiprazole, olanzapine, quetiapine, or risperidone. |
2020-09-23 |
2023-08-13 |
Not clear |